Oryzon Genomics S.A.

ORYZF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$5,571-$3,353-$4,231-$7,180
Dep. & Amort.$148$153$167$144
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC-$1,065$365$1,256$2,133
Other Non-Cash$799$2,260$961$1,276
Operating Cash Flow-$5,690-$575-$1,848-$3,626
Investing Activities
PP&E Inv.-$7,710$0-$76-$175
Net Acquisitions$0$0$0$0
Inv. Purchases-$102-$1-$1-$6
Inv. Sales/Matur.$0$0$0$43
Other Inv. Act.$0-$14,503-$14,195-$11,586
Investing Cash Flow-$7,811-$14,504-$14,271-$11,724
Financing Activities
Debt Repay.$5,374$7,901$9,642$4,123
Stock Issued$0$0$0$0
Stock Repurch.$0-$1,800-$1,000$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1,497-$80$68$0
Financing Cash Flow$6,871$6,021$8,710$4,123
Forex Effect-$9-$3$1$348
Net Chg. in Cash-$6,638-$9,060-$7,408-$10,880
Supplemental Information
Beg. Cash$12,257$21,317$28,725$39,605
End Cash$5,619$12,257$21,317$28,725
Free Cash Flow-$13,399-$15,078-$16,118-$15,388
Oryzon Genomics S.A. (ORYZF) Financial Statements & Key Stats | AlphaPilot